GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » Net Issuance of Debt

Kezar Life Sciences (FRA:2KZ) Net Issuance of Debt : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Kezar Life Sciences's net issuance of debt for the three months ended in Mar. 2024 was €0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Kezar Life Sciences Net Issuance of Debt Historical Data

The historical data trend for Kezar Life Sciences's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Net Issuance of Debt Chart

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Debt
Get a 7-Day Free Trial - - 8.44 - -

Kezar Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kezar Life Sciences Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kezar Life Sciences Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (FRA:2KZ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (FRA:2KZ) » Definitions » Net Issuance of Debt
Comparable Companies
ATHA ELTX VANI ANEB SPRO ACET TSBX IOBT ADCT KNTE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KZR:USA 2KZ:Germany
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.kezarlifesciences.com
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Kezar Life Sciences (FRA:2KZ) Headlines

No Headlines